Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ziprasidone + olanzapine
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intramuscular
01
Overview
Ziprasidone + olanzapine is a combination of two atypical (second-generation) antipsychotic drugs used in the management of schizophrenia and related psychotic disorders. Both agents act primarily as antagonists at dopamine D2 and serotonin 5HT2A receptors, but each has a unique receptor binding profile. Ziprasidone also inhibits norepinephrine and serotonin reuptake, while olanzapine exhibits broader antagonism across multiple dopamine, serotonin, adrenergic, histamine, and muscarinic receptors. Combination therapy may be considered for patients with inadequate response to monotherapy or to mitigate certain side effects such as metabolic syndrome associated with olanzapine alone. Clinical studies suggest that combining these agents can improve psychotic symptoms and reduce movement-related side effects without significantly increasing metabolic risk compared to monotherapy[1][4][8].
- Other names
- ziprasidone + olanzapine
02
Targets
ADRA1A (α1A)DRD1 (Dopamine D1 Receptor)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HRH1 (Histamine H1 Receptor)M1 (Muscarinic acetylcholine receptor M1)NET (Norepinephrine Transporter)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR6 (5-hydroxytryptamine receptor 6)SERT (Sodium-dependent serotonin transporter)mAChR (Muscarinic acetylcholine receptors)HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on ziprasidone + olanzapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ziprasidone + olanzapine.